Thursday, September 23, 2010
Strategy to build a complete catalogue of human proteins could put China in a leading position
Wednesday, September 15, 2010
Agorithm from Blood-Based Alzheimer's Biomarkers
Share |
Thursday, August 6, 2009
BioFocus, Oncodesign Strike Partnership
The agreement will create a service that combines BioFocus DPI's target discovery and screening capabilities with Oncodesign's biomarker and pharmacological services to offer target validation and clinical candidate selection services, the company said.
BioFocus DPI offers gene-to-drug candidate discovery services, including in vitro and cell-based screening, chemogenomic and informatics offerings, storage, distribution, and other structural biology and medicinal chemistry services.
XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.
- The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis
- Innovative Features like Semantic Search, Concept Linking, Bibliographic search, Save, Export and Visualize
- Only Knowledgebase with daily updations from PubMed
- XTractor Premium now at an Special Introductory Offer. Subscribe now and save!
- Request for a Trial
Thursday, June 4, 2009
Grants galore, US is recession profing by encoraging companies in biotechnology industry
Wisconsin will provide $250,000 to Integrated Genomics through a combination of a loan and a grant, and the company plans to relocate its laboratory and commercial operations from Chicago to Madison, the state's governor's office said Tuesday. The state will give the microbial genomics and gene expression services and technologies company a loan of $200,000 and a grant of $50,000 from the Technology Venture Fund. It said that Integrated Genomics' move could create up to 18 new jobs.
Compugen Gets $500K in Grants from Israel
The company plans to use the funding to pay for relocating the laboratory to Madison and to buy equipment. Wisconsin Governor Jim Doyle said in a statement that Integrated Genomics "is exactly the type of company our state should be investing in – companies that are developing innovative solutions in the biotechnology industry."
Compugen said today that it will receive grants totaling around $500,000 from the Office of the Chief Scientist of Israel to fund the firm's drug and diagnostic product candidate discovery activities. Tel Aviv, Israel-based Compugen said that it would use the grant money to discover additional drug targets for antibody therapeutics and preclinical nucleic acid biomarkers for drug-induced toxicity. The firm said these activities would be based on "modifying and enhancing" its 10 existing discovery platforms.
Compugen also said that it would use a portion of the funds to develop additional computational methods predicting genes, mRNA transcripts, proteins, and peptides that appear most suitable for development as therapeutic and diagnostic products.
XTractor Premium - A Platform for discovery, analysis and modelling of published biomedical facts.
- The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis
- Innovative Features like Semantic Search, Concept Linking, Bibliographic search, Save, Export and Visualize
- Only Knowledgebase with daily updations from PubMed
- XTractor Premium now at Introductory Offer of $450 for Academic Researchers. Subscribe now and save $300!
- Register for WebEx
- Request for a Trial
Tuesday, July 29, 2008
Blood Biomarkers for the Presence of Ruptured Atherosclerotic Plaques Identified
The presence of these antibodies was detected extremely early after the onset of symptoms of a heart attack, according to the investigators. They caution, though, that further studies on additional patients are needed before this work can be translated into the clinic.
Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.
Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.
Sunday, July 27, 2008
Molecular Connections perceives inorganic growth path
"The acquisition will depend on good technology fit and domain expertise that could plug into our products and services,'' Jignesh Bhate, CEO, Molecular Connections Pvt Ltd told Pharmabiz.
"We are aggressively scouting for companies both in India and abroad. If we lay our hands on an international company, we will have access to their customers. In the case of an Indian company, we are essentially looking at a synergy in content and database,'' Bhate said.
To facilitate these acquisitions, Molecular Connections has identified three options to raise funds: internal accruals, foreign loans and venture funds. The mode of raising capital will depend on the size of the deal and the company is in talks with foreign banks. Around $2 million was raised from Barings Private Equity in 2006 for expansion.
Early this month, Molecular Connections was adjudged as the most promising company of the year by CNBC-ICICI for the Emerging India Awards out of more than 3.5 lakh entries.
The company, with sound financials, was also recognized as one of the fastest growing companies in the Technology Fast 50 India 2007 survey conducted by Deloitte Touche Tohmatsu, Asia Pacific. Molecular Connections was ranked 8th in India in the overall category.
The six-year-old company's product portfolio of informatics solutions focuses on protein interaction mechanisms of biological processes and also Biomarkers. Its maiden offering NetPro, the largest database globally on protein-protein has been upgraded with pharmacokinetics model. This is a market leader with repeat subscriptions from GSK, Aventis, Merck, Becton & Dickenson's bio-pharma unit and Galapagos NV, a drug discovery company.
The second product, CliPro's new version has been supplemented with biomarker data for clinical data. A recent product, Receptome is a comprehensive database of Functional Ligand-Receptor Complexes. Another new product, 'Xtractor' is a literature alert service, giving manually curated sentences of keywords as given by scientists.
All products are targeted at international customers because investments in informatics are increasing globally and the sector is getting its due importance. India pharma-biotech space will take a few years to utilize informatics' solutions offered from Molecular Connections, stated Bhate.
With collaborations helping to open a new dimension in research, Molecular Connections has partnered with the Bangalore-based Connexious Life Sciences for pathway work. Recently, it has teamed up with the Indian Institute of Science for a department of Biotechnology grant. The company's CYP database will be utilized by Prof P Kondaiah from the Department of Molecular Reproduction, Development & Genetics to customize drugs for the Indian population.
The global informatics market is valued at $6-8 billion. Of these four areas comprising validation & target identification, clinical development including toxicity studies, lead optimization studies, part of combinatorial chemistry is estimated at $6-8billion. Right now, Molecular Connections has the expertise in validation & target identification and is honing its skills in the area of ADME/TOX side and combinatorial chemistry.
Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.
Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.
Friday, May 16, 2008
Biomarkers Predict Heart Deaths
And second one, Potential cardiovascular disease markers – CliPro™ based analysis:
Introduction
Quantitative analysis of proteins in body fluids for disease diagnosis has attained significant clinical relevance as it could reflect the pathophysiological state of the organism. Despite the wide concentration ranges and limitations of certain analytical techniques, the utility of the plasma proteome as a principle diagnostic material for biomarker analysis is on the rise (Anderson et al., 2002; Anderson et al., 2004; Adkins et al., 2002). Cardiovascular disease (CVD) is one of the leading causes of death, though preventable. Understanding of pathophysiological components and their role in diagnosis and timely prediction could become vital in this largely preventable disease. Analyzing the plasma proteome using CliPro™ has helped us to identify and validate potential biomarker-CVD disease association.
Using literature-mining efforts, we have systematically compiled a list of plasma proteins that contains concentration values reflecting alterations between normal versus various disease states. Using CliPro™, we found significant differences in the levels of some of the plasma proteins, influenced by genetics, sex, age, physiological state and various factors. Of the many protein candidates, we have prioritized a list of around 180 clinically significant plasma proteins of different types with their concentration ranges reflecting a clear-cut CVD association. By analyzing the concentration values of the plasma proteins in disease versus normal conditions, we find that more than 50% of the proteins clearly serve as biomarkers, which will enable to measure the presence/ progress of a disease or the effect of therapeutic intervention in the treatment of a disease.
Tuesday, May 6, 2008
Biomarkers to Open the Door to Personalized Medicine and Represents a Seismic Shift for the Pharma Industry
Some pharmaceutical companies are already advancing their research and harnessing the power of biomarkers, which can:
- Be used to detect the predisposition for disease in a population, screen for its presence, confirm its diagnosis, assess its severity, predict its response to available therapies and measure its clinical course
- Be used as targets to discover new drugs
- Be a decisive factor in determining whether or not to continue research on an entity
- Show early in the development phase whether an entity could lead to side effects that should terminate further research
- Help to make clinical trials more efficient
- Reduce treatment overheads by optimizing dosages and measuring a patient’s response more quickly and accurately
- Knowledgebase, is a result of manually mining thousands of papers, on proteins present in various human body fluids , with their known concentration values and biomarker information as available in literature
- Platform to analyze protein biomarker- disease associations
- Catalogue of clinically significant proteins in biofluids such as plasma, cerum, CSF, synovial fluid, saliva, urine, peritonial fluid, bal fluid, amniotic fluid, tears
- includes >1000 clinically significant proteins – with ~2000 different disease/pathological correlations
- Biomarkers with disease associations are broadly either diagnostic, prognostic, predictive or efficacy markers